Roche providing a challenge to leading ophthalmology players

10 May 2024
roche_logo_large

Swiss pharma giant Roche’s (ROG: SIX) Vabysmo (faricimab) is in the spotlight following its promising first-quarter 2024 sales figures.

Vabysmo, which gained US Food and Drug Administration (FDA) approval in January 2022, had sales of $927 million during the quarter.

The vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 inhibitor therapy, is indicated for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology